Arana

Arana Therapeutics, Ltd was an Australian biotechnology company focused on antibody development and traded on the ASX. Arana acquired Pepteck Limited and EvoGenix Limited to gain access to their EvoGene™ technologies to evolve antibodies and other proteins to improve their properties for use as therapeutic and diagnostic products. EvoGenix also had a proprietary binding scaffold with antibody-like properties called Evibodies™. Arana advanced a novel anti-TNF antibody into Phase III clinical trials before it was acquired by Cephalon, Inc. in 2009 for more than AU$200M.